ClearPoint Neuro, Inc. (CLPT) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for ClearPoint Neuro, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, ClearPoint Neuro, Inc.'s filing signal
continuing negative.
earningsVibe SuperAnalyst™ Verdict:
CONTINUING NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does ClearPoint Neuro, Inc. actually do?
Answer:
ClearPoint Neuro, Inc. is a commercial-stage medical device company specializing in integrated systems for minimally invasive neurosurgical procedures. The company's core offering, the ClearPoint system, guides the insertion of electrodes, needles, and catheters for deep brain stimulation, biopsies, and drug infusion, originally designed for MRI suites but now also supporting operating room procedures. Following its 2025 acquisition of IRRAS, ClearPoint expanded into neurocritical care with the IRRAflow system for intracranial fluid management. Beyond medical devices, ClearPoint also provides preclinical development services and consulting to pharmaceutical and biotech partners for drug delivery research. Its business model relies on recurring revenue from disposable components, complemented by capital equipment sales and services.
Question:
What are ClearPoint Neuro, Inc.'s revenue drivers?
Answer:
Revenue is driven by the sale of disposable components for its ClearPoint and IRRAflow systems, as well as sales of reusable hardware and software components. Additionally, revenue is generated from consulting and preclinical development services provided to pharmaceutical and biotech companies.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required